RO6889678 is primarily investigated for its potential therapeutic applications in the field of oncology, particularly as a targeted therapy for cancers driven by KRAS gene mutations. It is designed to inhibit the activity of abnormal proteins resulting from KRAS mutations, which are involved in tumor growth and proliferation, thereby slowing or halting cancer progression. Clinical trials are ongoing to evaluate its efficacy, safety, and optimal dosage in treating patients with advanced or refractory cancers harboring KRAS mutations. Additionally, researchers are exploring its potential use in combination with other anticancer agents to enhance treatment outcomes and overcome drug resistance. Its application represents a promising approach in precision medicine, aiming to provide more effective and tailored therapies for cancer patients.